Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Yum China Holdings Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15 (market cap $2.81B), while Yum China Holdings Inc trades at $43.53 (market cap $14.58B). The key difference: Yum China Holdings Inc is far larger — about 5.2× Dyne Therapeutics Inc. Common Stock's market cap, and Yum China Holdings Inc pays a 2.69% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Yum China Holdings Inc for 77 Days on average.
| DYN | YUMC | |
|---|---|---|
Market Cap | $2.81B | $14.58B |
Volume | 2,195,902 | 1,599,461 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $57.95 |
52-Week Low | $14.60 | $39.98 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.13B | $15.49B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
YUMC trades at $43.11, up 0.63% today, with a bullish technical signal and strong analyst support (14 Buy, 5 Hold). The stock shows consistent earnings beats, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80B in 2025, and net income reached $929M. Recent corporate actions include a $0.29 dividend and the acquisition of Pizza Hut brand ownership in Mainland China, enhancing long-term growth prospects.
YUMC presents a favorable investment case with solid fundamentals, reasonable valuation (P/E 15.69), and positive earnings momentum. Key risks include competitive pressures in China's restaurant sector and macroeconomic sensitivity. Wall Street's average price target implies a 25.6% upside, supporting a bullish outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
